Sign in Subscribe
Stem cells

Long-Term Outcomes of Autologous Stem Cell Transplantation in Mantle Cell Lymphoma Patients

Strategic Insights

— 1 min read

Researchers at the Medical University of Silesia in Poland have conducted a study to evaluate the long-term outcomes of autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma (MCL). The study, published in the Annals of Hematology, included 119 patients who underwent ASCT between 2007 and 2024 in first complete or partial remission. The findings suggest that ASCT remains a safe and effective consolidation approach in MCL, offering favorable long-term survival. However, the presence of B symptoms at diagnosis and use of CBV conditioning were independently associated with inferior overall survival and progression-free survival.

Key Takeaways:

  • 119 patients with MCL underwent ASCT between 2007 and 2024 in first complete or partial remission.
  • At 3 and 5 years, overall survival (OS) rates were 78.3% and 75.2%.
  • Progression-free survival (PFS) rates were 76.6% and 73.4%.
  • The presence of B symptoms at diagnosis and use of CBV conditioning were independently associated with inferior OS and PFS.
  • BeEAM conditioning was associated with improved outcomes.
  • Treatment-related mortality at day 100 was 3.4%.
  • Post-transplant complications occurred in 64% of patients, most commonly infections and mucositis.
  • Rituximab maintenance was used in only 17% of cases.
  • The median time to relapse was 13 months, and relapse remained the leading cause of treatment failure.
  • ASCT remains a safe and effective consolidation approach in MCL, offering favorable long-term survival.

Statistics:

  • 119 patients underwent ASCT in the study period.
  • 78.3% and 75.2% overall survival rates at 3 and 5 years, respectively.
  • 76.6% and 73.4% progression-free survival rates at 3 and 5 years, respectively.
  • 3.4% treatment-related mortality rate at day 100.
  • 64% of patients experienced post-transplant complications.
  • 17% of patients received rituximab maintenance.
  • 13 months median time to relapse.

Sources:

  • NewsRx. Data on Mantle Cell Lymphoma Described by Researchers at Medical University of Silesia ("B" symptoms and CBV conditioning negatively impact survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation). Hematology Week. October 20, 2025; p 342.
  • Annals of Hematology. "B" symptoms and CBV conditioning negatively impact survival in mantle cell lymphoma patients undergoing autologous stem cell transplantation. 2025.

Read more